Phase 2 Basket Trial Of Nab-Sirolimus In Patients With Malignant Solid Tumors With Pathogenic Alterations In Tsc1/?Tsc2 Genes (Precision 1)
Posted Date: Apr 26, 2024
- Investigator: Davendra Sohal
- Type of Study: Drug
tudy TSC-007 is a prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety profile of nab-sirolimus administered to patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. Patients will be treated with single agent IV nab-sirolimus until disease progression, or unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion.
Criteria:
Null
Keywords:
Solid Tumors
For More Information:
Kayla Webb
NULL
cancer@uchealth.com